CollPlant Biotechnologies (CLGN) Scheduled to Post Quarterly Earnings on Thursday

CollPlant Biotechnologies (NASDAQ:CLGNGet Free Report) is scheduled to announce its earnings results before the market opens on Thursday, April 4th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

CollPlant Biotechnologies Stock Performance

CLGN stock opened at $5.26 on Wednesday. The company has a market capitalization of $60.23 million, a PE ratio of -8.62 and a beta of 0.24. CollPlant Biotechnologies has a 12-month low of $4.22 and a 12-month high of $8.90. The business’s fifty day moving average price is $5.32 and its 200 day moving average price is $5.48.

Institutional Investors Weigh In On CollPlant Biotechnologies

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in CollPlant Biotechnologies by 53.9% during the 1st quarter. Bank of America Corp DE now owns 7,389 shares of the company’s stock worth $52,000 after purchasing an additional 2,589 shares during the period. UBS Group AG increased its holdings in CollPlant Biotechnologies by 119.1% during the 2nd quarter. UBS Group AG now owns 7,514 shares of the company’s stock worth $60,000 after purchasing an additional 4,085 shares during the period. Credit Suisse AG purchased a new stake in CollPlant Biotechnologies during the 4th quarter worth about $51,000. Jane Street Group LLC purchased a new stake in CollPlant Biotechnologies during the 3rd quarter worth about $90,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CollPlant Biotechnologies during the 2nd quarter worth about $189,000. Hedge funds and other institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

(Get Free Report)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.

See Also

Earnings History for CollPlant Biotechnologies (NASDAQ:CLGN)

Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.